HOME > word lists > Clinical Trial Acronyms: A to L

word lists

Clinical Trial Acronyms: A to L

• 4S: Scandinavian simvastatin survival study; MT Desk glossary
• 6C trial: cooperative colorectal cancer combination chemotherapy clinical; MT Desk glossary
• AAASPS: African-American antiplatelet stroke prevention study; MT Desk glossary
• AASK: African-American study of kidney disease and hypertension
• ABC study: Association of Black Cardiologists study of hypertension; MT Desk glossary
• ABCD:
  • alternans before cardioverter-defibrillator
  • appropriate blood pressure control in diabetes
• AbESTT: abciximab [ReoPro™] in emergent stroke treatment trial
• ACADEMIC: azithromycin in coronary artery disease: elimination of myocardial infection with chlamydia
• ACAS: asymptomatic carotid atherosclerosis study; MT Desk glossary
• ACCENT: A Crohn's disease clinical trial evaluating infliximab in a new long-term treatment regimen
• ACCESS:
  • acute candesartan cilexetil evaluation in stroke survivors
  • a case control etiological study of sarcoidosis
• ACCORD: action to control cardiovascular risk in diabetes
• ACES:
  • Avelox™ clinical experience study
  • azithromycin and coronary events study
• ACME: angioplasty compared to medicine
• ACIP: asymptomatic cardiac ischemia pilot study
• ACRE: appropriateness of coronary revascularization
• ACST: asymptomatic carotid surgery trial
• ACT:
  • angioplasty compliance trial
  • attacking claudication with ticlopidine
• ACTION:
  • a clinical trial in overt nephropathy; MT Desk glossary
  • actinomycin eluting stent improves outcomes by reducing neointimal hyperplasia
  • a coronary disease trial investigating outcome with nifedipine GITS
• ACUTE:
  • analysis of coronary ultrasound thrombolysis endpoints in acute myocardial infarction; Angiosonics
  • assessment of cardioversion utilizing transesophageal echocardiography; MT Desk glossary
• ADAM:
  • Amsterdam duration of antiretroviral medication study
  • aneurysm detection and management study
• ADAPT: Alzheimer's disease anti-inflammatory prevention trial; MT Desk glossary
• ADCS: Alzheimer's disease cooperative study
• ADEMEX: adequacy of peritoneal dialysis in Mexico; sponsor: Baxter Healthcare Corporation
• ADEPT: advanced elements of pacing trial; sponsor: Medtronic
• ADMIRAL: abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term followup
• ADMIT: arterial disease multiple intervention trial
• ADONIS: aspirin dose optimized in noncardioembolic ischemic stroke
• ADOPT: a diabetes outcome progression trial; MT Desk glossary
• ADOPT-A: atrial dynamic overdrive pacing trial-A
• ADVANCE: a dosing evaluation of a vasopressin antagonist in CHF patients undergoing exercise
• AEGIS: alternative graft investigational study; MT Desk glossary
• AFCAPS: Air Force coronary atherosclerosis prevention study
• AFFIRM: atrial fibrilation followup: investigation of rhythm management
• AFIB: atrial fibrillation investigation with bidisomide
• AGENT: angiogenic gene therapy
• AGIS: advanced glaucoma intervention study
• A-HeFT: African-American heart failure trial; MT Desk glossary
• AIR: aerosolized iloprost randomized placebo-controlled study; sponsor: Schering AG
• AIST-ASH: acute ischemic stroke trial: oral aspirin vs intravenous heparin on stroke progression
• ALERT:
  • adjunctive Lamictal® in epilepsy and response to treatment
  • assessment of Lescol® in renal transplantation
• ALIVE:
  • adenosine lidocaine infarct zone viability enhancement
  • amiodarone versus lidocaine in prehospital ventricular fibrillation evaluation; sponsor: Wyeth Pharmaceuticals
  • azimilide postinfarct survival evaluation; MT Desk glossary
• ALLHAT: antihypertensive and lipid-lowering treatment to prevent heart attack trial; MT Desk glossary
• ALLIANCE: aggressive lipid lowering to alleviate new cardiovascular endpoints
• ALTS: ASCUS/LSIL triage study [ASCUS - atypical squamous cells of undetermined significance; LSIL - low-grade squamous intraepithelial lesion]
• AMAZE: a multicenter trial using Atacand®-Zestril®* versus Zestril to evaluate the effects on lowering blood pressure [*Atacand as add-on therapy with Zestril]
• AMIGO: AC2993: diabetes management for improving glucose outcomes; sponsor: Amylin Pharmaceuticals, Inc.
• AMISTAD: acute myocardial infarction study of adenosine; MT Desk glossary
• APASS: antiphospholipid antibody stroke study
• APC: adenoma prevention with celecoxib; MT Desk glossary
• APOCARD: Apomate™ imaging in cardiac transplant patients
• APRES: angiotensin-converting enzyme inhibition post revascularization study
• ARCH: amiodarone reduction in coronary heart
• ARCHeR: Acculink™ for revascularization of carotids in high-risk patients
• AREDS: age-related eye disease study
• ARIC: atherosclerosis risk in communities
• ARMS: APSAC reocclusion multicenter study
• ARREST: AngioRad™ radiation for restenosis; MT Desk glossary
• ARTISTIC: AngioRad™ radiation therapy for in-stent restenosis intracoronary; MT Desk glossary
• ASAP: azimilide supraventricular arrhythmia program; MT Desk glossary
• ASCENT: ACS stent clinical equivalence in de novo lesions trial
• ASCOT: Anglo-Scandinavian cardiac outcome trial
• ASPECT: anticoagulants in the secondary prevention of events in coronary thrombosis; MT Desk glossary
• ASPEN: atorvastatin [Lipitor™] study for the prevention of endpoints for patients with NIDDM
• ASSENT: assessment of the safety and efficacy of a new thrombolytic [TNKase™]; MT Desk glossary
• ASTIS: autologous stem cell transplantation international scleroderma trial
• ASTRID: atrial sensing trial to prevent inappropriate detections
• ASTRONAUT: acid suppression trial: ranitidine [Zantac®] versus omeprazole [Prilosec®] for NSAID-associated ulcer treatment
• ATAC:
  • Arimidex (anastrozole), tamoxifen and combination therapy
  • Arimidex (anastrozole) and tamoxifen alone or in combination
• ATBAT: anticoagulant therapy with bivalirudin [Angiomax™] to assist in PCI 1st inning trial (PCI in HIT/HITTS)
• ATICH: antifibrinolytic therapy in acute intracerebral hemorrhage
• ATLAS:
  • Acolysis during treatment of lesions affecting saphenous vein bypass grafts; Angiosonics' Acolysis System™
  • assessment of treatment with lisinopril and survival; MT Desk glossary
• ATLANTIC: angina treatments – lasers and normal therapies in comparison
• ATLANTIS: alteplase thrombolysis for acute noninterventional therapy in ischemic stroke
• AT LAST: antiretroviral trial looking at sex and treatment
• AtoZ: Aggrastat® to Zocor® study; sponsor: Merck
• ATRIA: anticoagulation and risk factors in atrial fibrillation
• ATS: amblyopia treatment study
• ATTRACT:
  • anti-TNF trial in rheumatoid arthritis with cA2 treatment; MT Desk glossary
  • anti-TNF trial in rheumatoid arthritis with concomitant therapy
• AVASIS: aspirin versus anticoagulants in symptomatic intracranial stenosis
• AVERT:
  • artificial valve endocarditis reduction trial
  • atorvastatin versus revascularization treatments
• AVID: antiarrhythmics versus implantable defibrillators
• AWESOME: angina with extremely serious operative mortality evaluation
• AZACS: azithromycin in acute coronary syndromes
• BARI: bypass angioplasty revascularization investigation
• BARI 2D: bypass angioplasty revascularization investigation 2 diabetes; MT Desk glossary
• BARS: Beaumont alcohol restenosis study
• BASC: blood pressure in acute stroke collaboration
• BATMAN: BiodivYsio® batimastat SV stent versus balloon angioplasty for the reduction of restenosis in small coronary arteries; MT Desk glossary
• BCPT: breast cancer prevention trial
• BEAT: bucindolol evaluation in acute myocardial infarction trial; MT Desk glossary
• BECAIT: bezafibrate coronary atherosclerosis intervention trial
• BELLES: beyond endorsed lipid lowering with EBCT scannings
• BENEFIT: Betaferon® [Betaseron® in U.S.] in newly emerging MS for initial treatment; information
• BENESTENT: Belgium Netherlands stent
• BERT: beta energy restenosis trial; MT Desk glossary
• BESMART: beStent™ in small arteries
• BEST: beta-blocker evaluation of survival trial; MT Desk glossary
• BEST-ICD: beta-blocker evaluation of survival trial plus ICD
• BETTER: beta radiation trial to eliminate restenosis; MT Desk glossary
• BHACAS: beating heart against cardioplegic arrest studies
• BIP: bezafibrate infarction prevention
• BLIND-DATE: blinded withdrawal of deprenyl in the DATATOP extension trial
• BLOSS: beta blocker length of stay study
• BPAV: balloon prophylaxis of aneurysmal vasospasm
• BRAINS:
  • Bayer randomized acute ischemia neuroprotectant study
  • biochemical research and information study
• BRAVO:
  • beta radiation for treatment of arteriovenous graft outflow; sponsor: Novoste Corporation [Corona™ system]
  • blockade of the GP IIb/IIIa receptor to avoid vascular occlusion; MT Desk glossary
• BREATHE-1: bosentan [Tracleer™]: randomized trial of endothelin receptor antagonist therapy for pulmonary hypertension
• BRILLIANT: batimastat (BB-94) antirestenosis trial utilizing the BiodivYsio® local drug delivery PC stent; MT Desk glossary
• BRITE: beta radiation to reduce in-stent restenosis; MT Desk glossary
• BRITE-SVG: beta radiation to reduce in-stent restenosis for saphenous vein bypass grafts
• CABERNET: carotid artery revascularization using the Boston Scientific EPI FilterWire EX and the EndoTex NexStent
• CACHET: comparison of abciximab complications with Hirulog® [Angiomax™ as of 1999] ischemic events trial
• CADILLAC: controlled abciximab [ReoPro™] and device investigation to lower late angioplasty complications
• CAESAR: Canada, Australia, Europe, South Africa AIDS study; MT Desk glossary
• CALM: candesartan and lisinopril microalbuminuria study
• CALM-PD: comparison of the agonist pramipexole vs. levodopa on motor complications in Parkinson disease
• CALYPSO: cylexin as an adjunct to lytic therapy to prevent superoxide reflow injury
• CAMELOT: comparison of amlodipine versus enalapril [Lipitor®] to limit occurrences of thrombosis
• CAMEO: cerebral aneurysm multicenter European Onyx™
• CANDLE: candesartan versus losartan efficacy comparison; MT Desk glossary
• CAPARES: coronary angioplasty amlodipine restenosis study
• CAPRICORN: carvedilol post infarction survival control in left ventricular dysfunction
• CAPRIE: clopidogrel versus aspirin in patients at risk of ischemic events; MT Desk glossary
• CAPT: complications of AMD [age-related macular degeneration] prevention trial
• CAPTEN: captopril after thrombolysis trial; MT Desk glossary
• CAPTIM: comparison of angioplasty and prehospital thrombolysis in acute myocardial infarction
• CAPTIN:
  • captopril before reperfusion in acute myocardial infarction
  • captopril plus tissue plasminogen activator following acute myocardial infarction
• CAPTURE: c7E3 antiplatelet therapy in unstable refractory angina
• CARDIA: coronary artery risk development in young adults
• CARDS: collaborative atorvastatin [Lipitor™]and diabetes study
• CARE:
  • calcium antagonist in reperfusion; MT Desk glossary
  • cholesterol and recurrent events; MT Desk glossary
  • carvedilol atherectomy restenosis; MT Desk glossary
• CARE-HD: coenzyme Q₁₀ and remacemide: evaluation in Huntington disease
• CARE-HF: cardiac resynchronization - heart failure; European complement to U.S./Canada MIRACLE study
• CARISA: combination assessment of ranolazine in stable angina; MT Desk glossary
• CARMEN: carvedilol ACE inhibitors remodelling mild heart failure evaluation
• CART: Canadian antioxidant restenosis trial
• CASES: Canadian activase for stroke effectiveness study
• CASH: cardiac arrest study-Hamburg
• CAST: cardiac arrhythmia suppression trial; MT Desk glossary
• CASTLE: candesartan amlodipine study of tolerability and efficacy
• CAT:
  • Chinese ACE inhibitor in acute myocardial infarction trial
  • cardiomyopathy trial
• CATAPULT: cisplatin and tirapazamine in subjects with advanced previously untreated non–small cell lung tumors
• CATIE: clinical antipsychotic trials of intervention effectiveness; see trial information
• CATS:
  • Canadian American ticlopidine study
  • captopril and thrombolysis study
• CAVATAS: carotid and vertebral artery transluminal angioplasty study
• CBT-CD: cognitive behavior therapy for the chronic depressions; MT Desk glossary
• CEDARS: comprehensive evaluation of defibrillators and resuscitative shock
• CEOS: congenital esotropia observational study
• CHAMP:
  • children's HIV and AIDS model program
  • combination chemotherapy and mortality prevention
• CHAMPIONS: controlled high-risk subjects Avonex™ MS prevention in ongoing neurologic surveillance
• CHAMPS: controlled high-risk subjects Avonex™ MS prevention study
• CHARM: candesartan cilexitil [Atacand™] in heart failure assessment of reduction mortality and morbidity
• CHEESE: comparative trial of HIV-infected patients evaluating efficacy and safety of saquinavir-enhanced oral formulation and indinavir given as part of a triple drug therapy; MT Desk glossary
• CHF-STAT: congestive heart failure survival trial of antiarrhythmic therapy
• CHRISTMAS: carvedilol hibernation reversible ischemia trial; marker of success
• CHS:
  • cardiovascular health study
  • Charleston heart study
  • community health study
  • Congenital Heart Surgeons Society study
  • coronary heart study
• CIBIS: cardiac insufficiency bisoprolol study
• CIDS: Canadian implantable defibrillator study; sponsor: Medtronic
• CIGTS: collaborative initial glaucoma treatment study
• CLASS:
  • celecoxib [Celebrex®] long-term arthritis safety study
  • clomethiazole acute stroke study
• CLASSICS: clopidogrel [Plavix™] aspirin stent international cooperative study
• CLASS-IHT: clomethiazole acute stroke study in ischemic, hemorrhagic, and tPA treated stroke
• CLEERE: collaborative longitudinal evaluation of ethnicity and refractive error
• COAST: heparin-coated stents in small coronary arteries
• COCAD: cognitive outcomes in coronary artery disease
• COLA: carvedilol open label assessment
• COMBINE: combining medications and behavorial interventions; MT Desk glossary
• COMET: carvedilol or metoprolol European trial
• COMMA: compliment inhibition in myocardial infarction treated with percutaneous transluminal coronary angioplasty [evaluation of IV dosing regimens of h5G1.1-scFv]; sponsors: Procter & Gamble and Alexion Pharmaceuticals
• COMPANION: comparison of medical therapy, pacing and defibrillation in chronic heart failure; Guidant Corporation
• COMPLY: compliment inhibition in myocardial infarction treated with thrombolytics [evaluation of IV dosing regimens of h5G1.1-scFv]; sponsors: Procter & Gamble Pharmaceuticals and Alexion Pharmaceuticals
• COMS: collaborative ocular melanoma study
• CONVINCE: controlled onset verapamil investigation of cardiovascular endpoints
• COOL: cardiovascular thrombolytic to open occluded lines [t-PA]
• COOL AID: cooling for acute ischemic brain damage; MT Desk glossary
• COOL MI: cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction; MT Desk glossary
• COPERNICUS: carvedilol [Coreg®] prospective randomized cumulative survival
• COPPA: clinical outcomes from the prevention of postoperative arrhythmia
• CORE: continuing outcomes relevant to Evista™
• COSS: carotid occlusion surgery study
• COURAGE: clinical outcomes utilizing revascularization and aggressive drug evaluation; MT Desk glossary
• COURT: a randomized trial of contrast media utilization in high risk PTCA
• CRASH: corticosteroid randomization after significant head injury
• CREDO : clopidogrel [Plavix™] for reduction of events during observation
• CREST: carotid revascularization endarterectomy vs stenting trial
• CRUISE: can routine ultrasound influence stent expansion
• CURE: clopidogrel in unstable angina to prevent recurrent ischemic events
• DAIS: diabetes atherosclerosis intervention study
• DAISY: diabetes autoimmunity study in the young
• DATATOP: deprenyl and tocopherol antioxidative therapy of parkinsonism
• DAVID: dual-chamber and VVI implantable defibrillator; see MT Desk glossary
• DEBATE: Doppler endpoints balloon angioplasty trial Europe; MT Desk glossary
• DECOPI: la desobstruction coronaire en post-infarctus
• DEFINITE: defibrillators in nonischemic cardiomyopathy treatment evaluation
• DEFUSE: diffusion-weighted imaging evaluation for understanding stroke evaluation; MT Desk glossary
• DESTINI-CFR: Doppler endpoints stenting international investigation - coronary flow reserve; MT Desk glossary
• DIADS: depression in Alzheimer disease study
• DIAGNOSIS: diffusion-weighted imaging assessment of the genuine need for other studies in ischemic stroke
• DIAMOND: distensibility improvement with ALT-711 remodeling in diastolic heart failure; sponsor: Alteon Inc.
• DIAMOND CHF: Danish investigators of arrhythmia and mortality on dofetilde   congestive heart failure; MT Desk glossary
• DIGAMI: diabetes mellitus insulin-glucose infusion in acute myocardial infarction
• DMIST: digital mammographic imaging screening trial
• DINAMIT: defibrillation in acute myocardial infarction trial
• DIRECT: diabetic retinopathy candesartan trial; candesartan cilexetil (Atacand®)
• DIRECTOR: direct stenting study with Orbus R stent™; sponsor: Orbus Medical Technologies
• DISC: disability in strategies for care
• DISTINCT: BiodivYsio™ stent in controlled trial
• DPT-1: diabetes prevention trial - type 1; MT Desk glossary
• DREAM: diabetes reduction approaches with ramipril and rosiglitazone medications
• DYSBOT: Dysport and Botox study; MT Desk glossary
• EAGAR: estrogen and graft atherosclerosis research trial
• EARS: European atherosclerosis research study
• ECCO 2000: effects of citicoline (CerAxon™) on clinical outcome - 2000 mg; MT Desk glossary
• EDGE™: evaluation of daptomycin [Cidecin™] in gram-positive entities
• EDGE^CAP: evaluation of daptomycin [Cidecin™] in gram-positive entities in the treatment of community-acquired pneumonia
• EDGE^SST: evaluation of daptomycin [Cidecin™] in gram-positive entities in the treatment of complicated skin and soft tissue infections
• EDGE^UTI: evaluation of daptomycin [Cidecin™] in gram-positive entities in the treatment of complicated urinary tract infection
• ED-IMPACT: emergency department impedance cardiography-aided assessment changes therapy; sponsor: CardioDynamics International
• EFICAT: ejection fraction in cardiac transplant patients
• EGASIS: early GABA-ergic activation study in stroke
• ELECT: evaluating enoxaparin [Lovenox®] clotting times; see MT Desk glossary
• ELITE: evaluation of losartan in the elderly
• ELLDOPA: earlier versus later levodopa in Parkinson disease
• ENABLE: endothelin antagonist bosentan for lowering cardiac events in heart failure
• ENCORE: evaluation of nifedipine and cerivastatin on the recovery of endothelial function; web site
• ENRICHD: enhancing recovery in coronary heart disease
• ENTIRE: enoxaparin and TNK-tPA with or without GP IIb/IIIa inhibitor as reperfusion strategy in ST elevation MI [TIMI-23]; MT Desk glossary
• EPHESUS:
  • eplerenone neurohormonal efficacy and survival study; MT Desk glossary
  • eplerenone post-AMI heart failure efficacy and survival study
• EPIC: evaluation of c7E3 for prevention of ischemic complications
• EPILOG: evaluation in PTCA to improve long-term outcome with abciximab GP IIb/IIIa blockade; MT Desk glossary
• EPISTENT: evaluation of platelet IIb/IIIa inhibitor for stenting trial
• ERA:
  • early rheumatoid arthritis (RA) study
  • enoxaparin restenosis after angioplasty study
  • estrogen replacement and atherosclerosis study
• ERASE: emergency room assessment of sestamibi for evaluation of chest pain
• ERGO: etomoxir for the recovery of glucose oxidation
• ER-TIMI: early Retavase™ - thrombolysis in myocardial infarction
• ESCAPE: evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness
• ESPRIT:
  • enhanced suppression of the platelet IIb/IIIa receptor with Integrilin™ therapy
  • European study of the prevention of reocclusion after initial thrombolysis
  • evaluation of subcutaneous proleukin in a randomized international trial
• ESPS2: European stroke prevention study 2
• ESSENCE: efficacy and safety of subcutaneous enoxaparin in non–Q-wave coronary events; MT Desk glossary
• ESSENTIAL: the studies of oral enoximone therapy in advanced heart failure; sponsor: Myogen, Inc.
• ETHECC: evaluation of Thymitaq™ in hepatocellular carcinoma; sponsor: Eximas Pharmaceutical Corporation
• ETROP: early treatment of retinopathy of prematurity
• Euro-SPAH: European-sonotherapy prevention of arterial hyperplasia; sponsor: PharmaSonics, Inc.
• EVIDENCE: evidence for interferon dose-effect: European-North American comparative efficacy study [Rebif® v. Avonex™ in relapsing-remitting multiple sclerosis (RRMS)]
• EVIDENT: endovascular investigation determining the safety of a new tacrolimus-eluting stent graft; sponsor: JOMED N.V.
• EXCITE: evaluation of oral xemilofiban in controlling thrombotic events; MT Desk glossary
• EXCITe: extremity constraint-induced therapy
• EXCLAIM: extended clinical prophylaxis in acutely ill medical patients [Lovenox™ (enoxaparin) postmarketing (phase IV) trial]; sponsor: Aventis
• FACET: fosinopril versus amlodipine cardiovascular events randomized trial
• FAME: fluvastatin [Lescol®] assessment of morbi-mortality in the elderly
• FASTER:
  • fibrinolytic and Aggrastat® ST elevation resolution; MT Desk glossary
  • first abarelix depot study for treating endometriosis rapidly
  • first and second trimester evaluation of risk; see study information
• FAST-MAG: field administration of stroke therapy - magnesium
• FIELD: fenofibrate [TriCor®] intervention and event lowering in diabetes
• FIRST:
  • Flolan (dobutamine) international randomized survival trial
  • first trimester integrated risk screening for trisomy [information]
• FLARE: fluvastatin [Lescol®] angiographic restenosis
• FOOD: feed or ordinary diet
• FOSIT: Fosamax® international trial
• FRAXIS / FRAX.I.S.: Fraxiparine® in ischemic syndromes
• FRIC: Fragmin® in unstable coronary artery disease
• FRISC: fast revascularization during instability in coronary artery disease
  Fragmin® during instability in coronary artery disease
• FROSTY: Freezor™ trial of supraventricular tachycardia
• FUSION: fractional flow reserve and ultrasound indices for objective narrowing assessment
• GART study: genotypic antiretroviral resistance testing
• GEMS: Ginkgo biloba evaluation memory study
• GISEN: gruppo Italiano di studi epidemiologici in nefrologia
• GUSTO: global utilization of streptokinase and tPA for occluded arteries; MT Desk glossary
• GUSTO-SPEED: global utilization of streptokinase and tPA for occluded arteries–strategies for patency enhancement in the emergency department
• HALT-C: hepatitis C antiviral long-term treatment to prevent cirrhosis; MT Desk glossary
• HANDLS: health aging in nationally diverse longitudinal samples
• HARDBALL: heart allograft rejection: detection with breath alkanes in low levels
• HeADDFIRST: hemicraniectomy and durotomy for deterioration from infarction relating swelling trial
• HEART: healing and early afterload reducing therapy
• HEAT 2: hypertension endothelin antagonist treatment
• HEME: hemorrhage early MRI evaluation
• HERO: Hirulog® early reperfusion/occlusion trial
• HERS: heart and estrogen/progestin replacement study
  HIV epidemiology research study
• HESTIA: home evaluation of stroke induced aid
• HIPS: heparin infusion prior to stenting; MT Desk glossary
• HIT:
  • HDL-cholesterol intervention trial
  • hirudin for the improvement of thrombolysis
• HOPE: heart outcomes prevention evaluation; MT Desk glossary
• HOPE-TOO: heart outcomes prevention evaluation - the ongoing outcomes
• HORIZON: health outcomes and reduced incidence with zoledronic once yearly
• HOT: hypertension optimum treatment
• HPS: heart protection study
• HRS: health and retirement study
• HYVET: hypertension in the very elderly trial
• ICE-IT: intravascular cooling adjunctive to primary coronary intervention
• ICSS: international carotid stenting study (CAVATAS-2)
• IDEAL:
  • incremental decrease in endpoints through aggressive lipid lowering
  • Iressa® dose evaluation in advanced lung cancer
• IDNT: irbesartan [Avapro®] in diabetic nephropathy trial
• IHAST: intraoperative hypothermia for aneurysm surgery trial
• IMAGES: intravenous magnesium efficacy in stroke
• IMAGINE: ischemic management with Accupril™ post bypass graft via inhibition of converting enzyme
• IMPACT:
  • Integrilin™ to manage platelet aggregation to prevent coronary thrombosis
  • international mexiletine or placebo antiarrhythmic coronary trial
  • international multiple sclerosis secondary progressive Avonex™ controlled trial
• IMPRESS: inhibition of metalloprotease by BMS-186716 in a randomized exercise and symptoms study; MT Desk glossary
• IMS: interventional management of stroke study
• INCOMIN: independent comparison of interferon [Betaseron® v. Avonex™ in relapsing-remitting multiple sclerosis (RRMS)]
• InDDEx: investigation into delay to diagnosis of Alzheimer disease with Exelon™
• INHIBIT: intimal hyperplasia inhibition with beta in-stent trial; Guidant Corporation
• INSIGHT: international nifedipine once-daily study – intervention as a goal in hypertension treatment; web site
• INTACT: Iressa® non–small cell lung cancer trial assessing combination treatment
• INTEGRITI: Integrilin® and tenecteplase [TNKase™] in acute myocardial infarction; MT Desk glossary
• InTIME: intravenous nPA for treatment of infarcting myocardium early; MT Desk glossary
• INTrEPID: investigation of non–transplant-eligible patients who are inotrope dependent; see MT Desk glossary
• INTRO-AMI: Integrilin® and reduced dose of thrombolytic in acute myocardial infarction
• IONA: impact of nicorandil in angina
• IONDT: ischemic optic neuropathy decompression trial
• IRAS: insulin resistance atherosclerosis study
• IRMA 2: irbesartan [Avapro®] microalbuminuria type 2
• IRIS: Isostent for restenosis intervention study
• ISAAC: international study of asthma and allergies in childhood
• ISAR: intracoronary stenting and antithrombotic regimen
• ISAR-STEREO: intracoronary stenting and angiographic results - strut thickness effect on restenosis outcome
• ISAT: international subarachnoid aneurysm trial
• ISTICH : international surgical trial in intracerebral hemorrhage
• ITT: intraventricular thrombolysis trial
• IVAT: intermediate sized vessel atherectomy trial
• L-CAD: lipid-coronary artery disease [pravastatin]; sponsor, Bristol-Myers Squibb
• LACI: laser angioplasty for critical ischemia; MT Desk glossary
• LAMP: locally advanced multimodality protocol; MT Desk glossary
• LARS: laser angioplasty in restenosed stents
• LaSRS: late steroid rescue study
• LATE: late assessment of thrombolytic efficacy; MT Desk glossary
• LEADER: lower extremity arterial disease event reduction
• LIDO: levosimendan [Simdax™] infusion versus dobutamine in low output heart failure
• LIDS: lumbar invertebrae disk study [device trial]
• LIFE: losartan intervention for endpoint reduction in hypertension
• LIMB: ultrasound lysing in lower extremities to minimize blood clots; Angiosonics
• LIMIT: long lesion intracoronary radiation to minimize intimal hyperplasia trial; sponsor: Guidant Corp. [Galileo™ intravascular radiotherapy system]
• LIPID: long-term intervention with pravastatin in ischemic disease; MT Desk glossary
• LONG WRIST: Washington radiation for in-stent restenosis trial for long lesions
• Look AHEAD: action for health in diabetes [Xenical; long-term study of effects of weight loss in type 2 diabetics]
• L-TAP: lipid treatment assessment project
• LV3P-CHF: left ventricular pacing in pacemaker patients with congestive heart failure (CHF); sponsored by St. Jude Medical

View clinical trial acronyms M to Z.